Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Hi Iberia Ingenieria Y Proyectos Sl |
| Country | Spain |
| Start Date | Dec 01, 2024 |
| End Date | Nov 30, 2028 |
| Duration | 1,460 days |
| Number of Grantees | 8 |
| Roles | Coordinator; Associated Partner; Participant |
| Data Source | European Commission |
| Grant ID | 101156751 |
The prevalence of Non-Communicable Diseases is forcing countries to consider different initiatives aimed at reducing the burden and impact of these diseases.In this sense, SHIELD pioneers an innovative approach to preventing cardiovascular diseases (CVD) and diabetes at all stages of disease and considering the strong relationship among them.
Utilizing advanced AI, SHIELD offers personalized interventions following a hierarchical model based on patients' risk profiles.
These profiles are continuously assessed through risk stratification and disease progression tools, leading to low, moderate, and high-risk layers, each requiring distinct prevention strategies, from halting disease progression to preventing relapse and complications.Initial risk assessment will include genetics, demographics, socio-economic status, environment, behavior, and medical conditions, using datasets like SHARE or ELSA, and retrospective hospital data (4,500+ patients).
Later-stage disease analysis will also entail polypharmacy, treatment adherence, wearables, psychosocial factors, PROMs, and PREMs, allowing for individualized interventions and real-time alerts for professionals through the SHIELD dashboard.
SHIELD also prioritizes the quality and security of these data, creating a standardized data homogenization model and federated learning approach to keep sensitive data locally.
Transparency is provided through explainable ML tools.Interventions are accessible via mobile apps, providing resources, recommendations, education, and local services.
Optimization algorithms enhance user engagement, and a chatbot, trained on patient data, offers continuous support with professional oversight.SHIELD will be validated in 3 pilots, involving more than 2,300 individuals along 2-years.
The aim is to get knowledge on the cost-effectiveness and efficacy of the prevention strategy proposed by SHIELD and to get insights for effective primary prevention pathways with population-wide impact.
Hi Iberia Ingenieria Y Proyectos Sl; Universite de Geneve; Quavlive Srl; University of Limerick; Consorzio Per la Ricerca Nell' Automatica E Nelle Telecomunicazioni C.R.A.T.; Servicio Madrileno de Salud; Universita Degli Studi Di Bari Aldo Moro; Universidad Politecnica de Madrid
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant